Walgreens Boots Alliance stock rises on better-than-expected sales and adjusted profit

Walgreens Boots Alliance (WBA) shares rose 0.8% in premarket trading after the company reported fiscal third-quarter results that surpassed Wall Street expectations, with adjusted profit of $0.38 per share against a $0.33 consensus and revenue reaching $38.99 billion compared to an estimated $36.84 billion. This positive performance occurs as the company proceeds with an approximately $10 billion private-equity deal to go private, a transaction that previously led to the withdrawal of its fiscal 2025 guidance.

Analysis

Walgreens Boots Alliance (WBA) reported a solid fiscal third quarter, exceeding analyst expectations on both revenue and adjusted profit. Revenue rose to $38.99 billion, significantly surpassing the FactSet consensus of $36.84 billion, while adjusted earnings per share came in at $0.38, a notable beat against the anticipated $0.33. This operational outperformance spurred a modest 0.8% rise in the company's shares in premarket trading. However, this positive financial performance is overshadowed by the major corporate event of a pending, approximately $10 billion private-equity deal to take the company private. Crucially, the company has cited this transaction as the reason for withdrawing its fiscal 2025 guidance, which effectively removes forward-looking visibility for public investors and shifts the investment thesis away from fundamentals towards the specifics of the M&A deal.

Key Decisions for Investors

• Investors should recognize that WBA's stock performance is now primarily driven by the pending go-private transaction, making it an M&A arbitrage opportunity rather than a play on fundamental growth.
• The strong earnings beat provides a positive operational signal and may support the valuation floor for the buyout, but its impact is secondary to news regarding the deal's progress and regulatory approval.
• The withdrawal of fiscal 2025 guidance significantly increases uncertainty for long-term holders, necessitating a focus on deal-completion risk and timeline rather than traditional performance metrics.